Home Applications Pharmaceutical & Biopharmaceutical Manufacturing Monoclonal Antibody ManufacturingRemoving Viruses From Your Downstream mAb Process

Removing Viruses From Your Downstream mAb Process

A scientist is diligently working in a laboratory, engaged in the downstream processing of monoclonal antibodies.

Downstream processing in the production of monoclonal antibodies (mAb) reduces the levels of virus by either removal or inactivation. Regardless of the technology, biomanufacturers must demonstrate the clearance capabilities of different downstream steps as part of the viral safety assessment process.

Downstream processing typically includes:

Chromatography – virus removal by binding affinity, charge or hydrophobicity
Chemical treatment – virus reduction by inactivation
Filtration – virus removal by size exclusion, a critical step for viral safety in most downstream processes
Demonstrating Effectiveness

Preventing Contamination in mAb Process
Preventing adventitious viruses in bioreactors is crucial; manufacturers implement upstream measures to safeguard biotherapeutic manufacturing.
Detecting Viral Contamination in mAb Process
Molecular testing enhances biomanufacturers' viral safety compliance and speed to results for raw materials and intermediates.
Monoclonal Antibody Manufacturing
Monoclonal antibody manufacturing requires scalable solutions ensuring high therapeutic concentration and process safety for immunotherapy.
See All (0)

Find More Articles and Protocols

Chromatography

To reach viral clearance targets, most downstream processes include at least two chromatography operations. A typical solution is protein A capture, followed by ion exchange chromatography (IEX), comprised of cation exchange chromatography (CEX) to reduce antibody aggregate levels and anion exchange chromatography (AEX) to remove residual host cell proteins and DNA. Under select conditions, both CEX and AEX can contribute to viral safety.

Chemical Treatment

Chemicals used for virus inactivation must meet the same high-quality standards as other raw materials. Selected chemicals should be manufactured or purified to GMP standards (based on the IPEC – PQG GMP guide for pharmaceutical excipients, 2006) for consistent high purity in order to assure process reliability. Chemicals with comprehensive testing and documentation packages simplify the compliance process.

Filtration

Removal of virus by filtration is typically based on size, with most mAb production processes relying on filtration to provide high levels of both enveloped and non-enveloped virus reduction. Virus filtration is regarded as a robust step for virus removal and is relatively insensitive to process conditions. However, the presence of protein aggregates and other trace fouling species can negatively impact the throughput performance of virus filters, resulting in increased filtration area requirements. For greater filtration efficiency, a prefiltration step to remove fouling species may be incorporated, leading to significant improvements in virus filter capacity, flux, and overall viral filtration costs.

Demonstrating Effectiveness

Manufacturers of biologics are required to evaluate their downstream manufacturing process for the ability of selected unit operations to inactivate or remove potential contaminants. Results of such clearance studies are required by regulatory authorities for investigational new drug (IND) submissions. Understanding these regulatory expectations is a key component of clearance study design, informing the manufacturer’s overall viral safety strategy.

Workflow

A scientist selects and pre-treats raw materials to safeguard downstream processes from potential adventitious viruses.

Preventing adventitious agent contamination

Careful selection and pretreatment of raw materials to prevent adventitious viruses from entering processes.

Learn More

Scientists in a lab analyze samples using microscopes. The setting is modern and busy, and a colorful cell image on a monitor.

Detecting viral contamination

Testing for the presence of viruses and other adventitious agents in cell banks, raw materials, and process intermediates.

Learn More

Monoclonal Antibody Manufacturing

Monoclonal antibody manufacturing is a highly templated approach used to produce mAb-based immunotherapies. Robust, scalable process solutions are required at every step to ensure high therapeutic concentration and process safety, while meeting speed-to-market and cost containment concerns.

Learn More

Related Webinars

A digital illustration of a laptop displaying a simplistic human figure next to a pink rectangle, all set against a yellow background.

Getting it Right. A Candid Conversation about Remote Viral Clearance Studies

Our head of project management discusses preparing for a viral clearance study from the client perspective with a technical specialist.

Viral Clearance with Viresolve^® Pro Solution: Prefiltration Strategies for Optimizing Performance

Learn how prefiltration technologies can significantly increase the performance of your viral clearance filter.

Parvovirus-Retentive Filter Performance and Removal Mechanisms During Process Interruptions

This presentation describes a case study using Viresolve^® Pro membrane filters where virus retention performance is characterized following process interruptions.

QBD for Downstream Virus Filtration

In this webinar, you will learn how to simplify validation study design, identify critical processes and feed parameters affecting virus retention, and compile a robust regulatory filing package.